Gastrointestinal stromal tumours (GIST): Biology and treatment

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 287-289

  Judson, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD34 ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYBRID PROTEIN; IFOSFAMIDE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESISTANCE; DRUG SELECTIVITY; EDEMA; ENZYME ACTIVATION; EXON; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; INDIGESTION; MOLECULAR BIOLOGY; NAUSEA; PRIORITY JOURNAL; RASH; SIGNAL TRANSDUCTION; SWEATING; SYMPTOMATOLOGY; TREATMENT PLANNING; TUMOR LOCALIZATION; WEIGHT REDUCTION;

EID: 0036434638     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf672     Document Type: Article

References (15)

1. Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumours of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology 1994; 25: 469-473.
2. Miettinen M, Virolainen M, Sarlomo-Rikala M. Gastro-intestinal stromal tumors: value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995; 19: 207-216.
3. Kindblom L-G, Remotti HE, Aldenborg F et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269.
4. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734.
5. Hirota. S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
6. Sircar K, Hewlett BR, Huizinga JD et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-389.
7. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunchistochemical and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1-12.
8. Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Clin Oncol 2001; 6: 1-5.
9. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nature Med 1996; 2: 561-566.
10. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
11. Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2185 patients treated with anthracycline-containing first-line regimens: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
12. Platt BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-3220.
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
14. Van Oosterom AT, Judson I, Verweij J et al. for the European Organisation for Research into Treatment for Cancer (EORTC). Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423.
15. Blanke CD, von Mehren M, Joensuu H et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, ST1571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing C-KIT (CD117). Proc Am Soc Clin Oncol 2001; 20: 1a.